scholarly journals Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients

2001 ◽  
Vol 92 (1) ◽  
pp. 96-105 ◽  
Author(s):  
Markus Feuerer ◽  
Marian Rocha ◽  
Lianhua Bai ◽  
Victor Umansky ◽  
Erich-Franz Solomayer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
T Cells ◽  
Cancer Patients ◽  
Memory T Cells ◽  
Breast Cancer Patients ◽  
Immunological Changes

Cellular immunotherapy in late stage breast cancer patients with reactivated autologous Memory T-cells (MTC) derived from bone marrow (BM)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 2612-2612
Author(s):  
F. Schuetz ◽  
K. Ehlert ◽  
G. Bastert ◽  
A. Schneeweiss ◽  
V. Schirrmacher ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
T Cells ◽  
Cancer Patients ◽  
Late Stage ◽  
Memory T Cells ◽  
Cellular Immunotherapy ◽  
Breast Cancer Patients

Immunological effects after an adoptive cellular immunotherapy with reactivated autologous memory T-Cells from bone marrow

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 12502-12502
Author(s):  
F. Schuetz ◽  
J. Rom ◽  
K. Ehlert ◽  
V. Schirrmacher ◽  
A. Schneeweiss ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
T Cells ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Memory T Cells ◽  
Ex Vivo ◽  
Cellular Immunotherapy ◽  
Breast Cancer Patients ◽  
Adoptive Cellular Immunotherapy

12502 Tumor-reactive CD4 and CD8 memory T cells (MTC) can be found in bone marrow (BM) of the majority of primary and metastatic breast cancer patients. In xenotransplant mouse models these cells, upon specific re-activation ex vivo, mediated efficient rejection of autologous breast tumors suggesting that the polyclonal natural MTC repertoire possesses therapeutic potential. In order to clinically exploit these anti-tumor capacities we treated 11 advanced metastasized breast cancer patients with autologous, tumor-reactive, reactivated MTC of BM in a phase-1 trial. Activation of T cells was done by MCF-7 lysate pulsed dendritic cells (DC). After reactivation both, T cells and pulsed DC were injected once intravenously. Peripheral blood was drawn on day 0, 1, 7, 14, 28. BM-re-aspiration was done on day 28 and 84. While TAA-reactive memory T cells were absent in the peripheral blood (PB) before therapy, 5 from 11 patients (=responders) showed TAA-specific PB T cell reactivity 7 days after therapeutic cell application suggesting a massive proliferation and mobilization into the blood of TAA-reactive T cells in these patients. A comparison of responders to adoptive cellular immunotherapy with non-responders revealed differences in the numbers of therapeutic cells that could be generated ex vivo and in the decreased frequency of tumor-reactive MTC in responders’ BM on days 28 and 84 which could be expained by a mobilization due to in situ activation by co-transferred DCs or due to local or systemic cytokine signals by transferred, activated T lymphocytes. Such effect might have contributed to the high numbers of circulating TAA-reactive T cells observed 7 days after the transfer. Furthermore we observed different concentrations of IL-4, IL-10, TNF-α, and INF-γ in PB and BM between the two groups leading to the hypothesis of a polarization in T cell responses (T1 type in responders vs T2 type in non-responders). No significant financial relationships to disclose.

Cellular immunotherapy in late stage breast cancer patients with reactivated autologous Memory T-cells derived from bone marrow

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 714-714 ◽  
Author(s):  
F. Schuetz ◽  
I. Diel ◽  
P. Beckhove ◽  
K. Ehlert ◽  
V. Schirrmacher ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
T Cells ◽  
Cancer Patients ◽  
Late Stage ◽  
Memory T Cells ◽  
Cellular Immunotherapy ◽  
Breast Cancer Patients

Cellular immunotherapy in late stage breast cancer patients with reactivated autologous Memory T-cells (MTC) derived from bone marrow (BM)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 2612-2612
Author(s):  
F. Schuetz ◽  
K. Ehlert ◽  
G. Bastert ◽  
A. Schneeweiss ◽  
V. Schirrmacher ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
T Cells ◽  
Cancer Patients ◽  
Late Stage ◽  
Memory T Cells ◽  
Cellular Immunotherapy ◽  
Breast Cancer Patients

scholarly journals Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1

2017 ◽  
Vol 66 (5) ◽  
pp. 593-603 ◽  
Author(s):  
Anchana Rathinasamy ◽  
Christoph Domschke ◽  
Yingzi Ge ◽  
Hans-Henning Böhm ◽  
Steffen Dettling ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
T Cells ◽  
Regulatory T Cells ◽  
Cancer Patients ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document